Reports Q1 revenue $141M, consensus $142.24M. Cash and cash equivalents and marketable securities were $371.8M as of March 31. “We delivered four major new products this quarter, which set a new standard for single cell and spatial biology,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “In its Q1 Visium HD helped drive strong growth in Spatial. We also had a significant number of customers trial our new GEM-X products, contributing to lower quarter-end orders for Chromium. Overall, we’re encouraged by the early enthusiasm, adoption and feedback from customers and believe these new launches will help accelerate growth as we move through the year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics Reports First Quarter 2024 Financial Results
- 10x Genomics price target lowered to $50 from $65 at Canaccord
- Cathie Wood’s ARK Investment buys 116.4K shares of 10x Genomics today
- 10x Genomics price target lowered to $55 from $60 at Deutsche Bank
- 10x Genomics price target lowered to $45 from $55 at Barclays